688163: announcement of initial offline placement results and online winning results of Salem biology’s initial public offering and listing on the science and Innovation Board

Shanghai Sailun Biotechnology Co., Ltd

Initial public offering and listing on the science and Innovation Board

Announcement of offline preliminary placement results and online Winning Results

Sponsor (lead underwriter): Founder Securities Co.Ltd(601901) underwriting sponsor Co., Ltd

hot tip

The application of Shanghai Sailun Biotechnology Co., Ltd. (hereinafter referred to as “Sailun biotechnology” or “the issuer”) for the initial public offering of RMB common shares (A shares) and listing on the science and Innovation Board (hereinafter referred to as “this offering”) has been examined and approved by the stock listing Committee of the science and Innovation Board of Shanghai Stock Exchange (hereinafter referred to as “Shanghai Stock Exchange”), The registration has been approved by the China Securities Regulatory Commission in the document of Zheng Jian Ke Ke [2022] No. 204.

This offering is conducted by a combination of directional placement to strategic investors (hereinafter referred to as “strategic placement”), offline inquiry placement to qualified investors (hereinafter referred to as “offline issuance”), and online pricing issuance to social public investors holding non restricted A-share shares and non restricted depositary receipts market value in Shanghai market (hereinafter referred to as “online issuance”).

The issuer and Founder Securities Co.Ltd(601901) underwriting and recommendation Co., Ltd. (hereinafter referred to as “recommendation Agency (lead underwriter)”) negotiated and determined that the number of shares issued this time is 27.06 million.

The initial strategic placement quantity of this issuance is 1353000 shares, accounting for 5.00% of the total quantity of this issuance. The subscription funds promised by the strategic investors have been fully remitted to the bank account designated by the sponsor (lead underwriter) within the specified time. The final number of strategic allotments in this issuance is 1211020 shares, accounting for 4.48% of the total number of this issuance. The difference between the initial number of strategic allotments and the final number of strategic allotments is 1419800 shares, which are transferred back to offline issuance.

After the callback of strategic placement and before the launch of online and offline callback mechanism, the number of offline issuance was 181369800 shares, accounting for 70.17% of the number issued after deducting the final number of strategic placement; The number of shares issued online was 7712000 million, accounting for 29.83% of the number issued after deducting the final strategic placement. The total number of final offline and online issuance is the total number of this issuance minus the final strategic placement, with a total of 25848980 shares.

The issue price is 33.03 yuan / share.

According to the announcement on the IPO arrangement and preliminary inquiry of Shanghai Salem Biotechnology Co., Ltd. and the announcement on the IPO and listing of Shanghai Salem Biotechnology Co., Ltd. on the science and Innovation Board (hereinafter referred to as the “issuance arrangement and preliminary inquiry announcement”) and the announcement on the IPO and listing of Shanghai Salem Biotechnology Co., Ltd. on the science and Innovation Board (hereinafter referred to as the “issuance announcement”) According to the announced callback mechanism, since the initial effective subscription multiple of this online offering is 460430 times, higher than 100 times, the issuer and the sponsor (lead underwriter) decided to start the callback mechanism, adjust the scale of offline and online issuance, and callback 2.585 million shares (rounded up to an integral multiple of 500 shares) from offline to online.

After the online and offline call back mechanism was launched, the final number of offline shares issued was 15551980 million, accounting for 60.16% of the total issued after deducting the number of strategic placement; The final number of shares issued online was 10.297 million, accounting for 39.84% of the total issued after deducting the number of strategic placements. After the callback mechanism was launched, the final winning rate of online issuance was Impulse (Qingdao) Healthtechco.Ltd(002899) 879%.

Investors are kindly requested to focus on the payment process of this offering and fulfill their payment obligations on March 2, 2022 (T + 2):

There are significant changes in the payment process of this offering, which investors are invited to pay attention to. The main changes are as follows: 1. Offline investors should, according to this announcement, timely and fully pay the subscription capital and the corresponding new share placement brokerage commission according to the final issue price of 33.03 yuan / share and the allocated quantity before 16:00 on March 2 (T + 2), 2022, The subscription funds and the corresponding brokerage commission for the placement of new shares shall be received before 16:00 on March 2 (T + 2) 2022.

The brokerage commission rate of new share placement of strategic investors and offline investors participating in this offering is 0.50% of their allocated amount (excluding the follow-up investment of relevant subsidiaries of the sponsor). The amount of brokerage commission for placing new shares of the placing object = the final amount allocated to the placing object × 0.50% (rounded to the nearest cent).

Offline investors are allocated multiple new shares every day. Please pay for each new share separately. In the case of multiple new shares allocated on the same day, if only one total amount is remitted, the consolidated payment will lead to the failure of accounting, and the resulting consequences shall be borne by the investors themselves.

After online investors win the bid for new shares, they shall fulfill the obligation of capital delivery in accordance with this announcement to ensure that their capital account will have sufficient capital for new shares on March 2 (T + 2) 2022. The insufficient part shall be deemed to give up the subscription, and the consequences and relevant legal liabilities arising therefrom shall be borne by the investors themselves. The transfer of investors’ funds shall comply with the relevant provisions of the securities company where the investors are located.

The shares that offline and online investors give up to subscribe for are underwritten by the sponsor (lead underwriter).

2. In this offline offering, securities investment funds and other partial share asset management products established by public offering, national social security fund, basic endowment insurance fund, enterprise annuity fund established in accordance with the measures for the administration of enterprise annuity fund Among the placement objects such as insurance funds and QFII funds that meet the relevant provisions of the measures for the administration of the use of insurance funds, 10% of the final allocation accounts (rounded up) shall promise that the holding period of the shares to be placed this time is 6 months from the date of the issuer’s initial public development and listing. The aforesaid restricted account will be determined by lottery after the offline investors complete the payment. The shares allocated to the placement target account managed by offline investors who have not been selected have no circulation restrictions and restricted sales arrangements, and can be circulated from the date when the shares issued this time are listed and traded on the Shanghai Stock Exchange. The lottery number of the online lower limit sale account will be allocated according to the placing object, and each placing object will be assigned a number. Once offline investors offer, they will be deemed to accept the online lower limit arrangement of this offering.

3. When the total number of shares paid and subscribed by offline and online investors is less than 70% of the number of shares issued after deducting the final strategic placement, the issuer and the sponsor (lead underwriter) will suspend the issuance of new shares and disclose the reasons for the suspension and subsequent arrangements.

4. If an offline investor with a valid quotation fails to participate in the subscription, fails to subscribe in full, or fails to pay the new share subscription fund and the corresponding new share placement brokerage commission in time and in full, it will be deemed as a breach of contract and shall bear the liability for breach of contract. The recommendation institution (lead underwriter) shall report the breach of contract to the China Securities Association for the record. If an online investor has won the lottery for 3 times but failed to pay in full within 12 consecutive months, it shall not participate in the online subscription of new shares, depositary receipts, convertible corporate bonds and exchangeable corporate bonds within 6 months (calculated as 180 natural days, including the next day) from the next day of the settlement participant’s latest declaration of abandonment of subscription.

The number of times of giving up subscription shall be calculated according to the number of times of investors actually giving up subscription of new shares, depositary receipts, convertible corporate bonds and exchangeable corporate bonds.

5. Once this announcement is published, it shall be deemed to have served the notice of allotment payment to the online investors who have participated in the online subscription and won the lot and all allotment objects who have obtained the allotment of offline issuance.

1、 Strategic placement results

(I) participants

In this offering, the selection of strategic placement investors is comprehensively determined after considering the guidelines for the application of the issuance and underwriting rules of the science and Innovation Board of Shanghai Stock Exchange No. 1 – initial public offering of shares (SZF [2021] No. 77) (hereinafter referred to as the “underwriting guidelines”), investor qualifications and market conditions, The strategic placement of this offering is that the relevant subsidiaries of the sponsor participate in the follow-up investment, and the follow-up investment institution is Founder Securities Co.Ltd(601901) Investment Co., Ltd. (hereinafter referred to as “founder investment”). There is no special asset management plan for senior executives and core employees and other strategic investor arrangements.

As of the date of this announcement, the above strategic investors have signed a placement agreement with the issuer. See the special verification report of Founder Securities Co.Ltd(601901) underwriting and recommendation Co., Ltd. on the strategic investors of Shanghai Sailun Biotechnology Co., Ltd. in the initial public offering and listing on the science and Innovation Board announced on February 25 (t-1) 2022 and Legal opinion of Beijing Tianda Gonghe law firm on the special verification of strategic investors of Shanghai Sailun Biotechnology Co., Ltd. in its initial public offering and listing on the science and innovation board.

(II) matching results

On February 24, 2022 (T-2), based on the preliminary inquiry results, the issuer and the recommendation institution (lead underwriter) negotiated and determined that the price of this issuance was 33.03 yuan / share, and the total scale of this issuance was 894 million yuan. According to the underwriting guidelines, the scale of this offering is less than 1 billion yuan, and the investment follow-up ratio of founder, the relevant subsidiary of the sponsor, is 5.00% of the scale of this offering, but no more than 40 million yuan. Founder investment has paid the subscription capital for strategic placement in full, and the number of shares allocated this time is 1211020, with an amount of 39999060 yuan. If the initial payment amount exceeds the corresponding amount of the final allocated shares, the sponsor (lead underwriter) will return the excess amount according to the original payment path of Founder investment before March 4, 2022 (T + 4).

The final strategic placement results of this offering are as follows:

Number of allotted shares allotted amount new share placement broker restricted period

Investor abbreviation (10000 shares) (yuan), excluding Commission (yuan), total (yuan) (month)

Gold)

Founder investment 12110203999999060 – 3999999060 24

Total 12110203999999060 – 3999999060-

2、 Online lottery results

According to the issuance announcement, the issuer and the recommendation institution (lead underwriter) held the lottery ceremony for the online issuance of shares of Shanghai Sailun Biotechnology Co., Ltd. on the morning of March 1, 2022 (T + 1) at the Haitang hall, the conference room on the fourth floor of Zijinshan Hotel, 778 Dongfang Road, Pudong, Shanghai. The lottery ceremony was conducted in accordance with the principles of openness, fairness and impartiality. The process and results of the lottery have been notarized by Shanghai Oriental notary office. The winning results are as follows:

Last digit winning lot number

Last “4” digits 924242

Last “5” digits 04633171332963342133354633671337963392133

The last “6” digits are 91575479075466575407554415754290754165754,

040754987492

The last “7” digits are 892086777670867642086751708673920867267,

142086701708679757221

The last “8” digits are 4203224819077178682055126467189951220138693593556,

eighteen million one hundred and ninety-seven thousand three hundred and five

If the mantissa of the subscription allotment number held by investors participating in the online issuance and subscription of Salem biological shares is the same as the above number, it is the winning number. There are 20594 winning numbers in total, and each winning number can only subscribe for 500 shares of Salem biology.

3、 Offline issuance and subscription and preliminary placement results

(I) offline issuance and subscription

According to the measures for the administration of securities issuance and underwriting (CSRC order [No. 144]), the measures for the implementation of stock issuance and underwriting on the science and Innovation Board of Shanghai Stock Exchange (SZF [2021] No. 76), the underwriting guidelines, and the underwriting specifications for initial public offerings under the registration system (czxf [2021] No. 213) In accordance with the requirements of the rules for the administration of offline investors in initial public offerings under the registration system and the guidelines for the classification, evaluation and management of offline investors in initial public offerings under the registration system (Zhong Zheng Xie Fa [2021] No. 212), the sponsor (lead underwriter) verified and confirmed the qualification of investors participating in offline subscription. According to the effective subscription results finally received by the offline electronic subscription platform of Shanghai Stock Exchange, the sponsor (lead underwriter) makes the following statistics:

The offline subscription of this offering has been completed on February 28, 2022 (t day). After verification, it is confirmed that the 7843 effective quotation placement objects managed by 346 offline investors disclosed in the issuance announcement have made offline subscription in accordance with the requirements of the issuance announcement. As an effective subscription investor, the number of offline effective subscription is 57948 million shares.

(II) preliminary offline placement results

According to the principles of offline placement published in the announcement of issuance arrangement and preliminary inquiry and the announcement of issuance

The results of the placement are as follows:

Type of placing object number of shares effectively subscribed amount of shares subscribed amount of shares allocated offline amount of shares allocated amount of investors allocated offline

- Advertisment -